Annual zoledronic acid infusion lowers risk of fracture, death

dc.contributor.author	Schumann, Sarah-Anne	eng
dc.contributor.author	Hickner, John	eng
dc.contributor.other	Family Physicians Inquiries Network	eng
dc.date.issued	2007	eng
dc.description.abstract	Patients with a prior hip fracture have 2.5 times the risk of a new fracture compared to age-matched persons without a previous hip fracture. For patients with a recent hip fracture, intravenous zoledronic acid annually is an option for reducing the risk of new fractures and death. Stength of recommendation (SOR) B: based on one well- designed randomized controlled trial.	eng
dc.identifier.uri	http://hdl.handle.net/10355/5403
dc.language	English	eng
dc.publisher	Family Physicians Inquiries Network	eng
dc.relation.ispartofcollection	Priority Updates to Research Literature (PURLs) (2007)	eng
dc.relation.ispartofcommunity	University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network	eng
dc.relation.ispartofseries	Journal of family practice, 56, no. 12 (December 2007): 1013-1016.	eng
dc.rights	OpenAccess.	eng
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.	eng
dc.subject.lcsh	Hip joint -- Fractures -- Treatment	eng
dc.subject.lcsh	Diphosphonates -- Therapeutic use	eng
dc.subject.other	Hip -- wounds and injuries	eng
dc.subject.other	Intravenous zoledronic acid	eng
dc.title	Annual zoledronic acid infusion lowers risk of fracture, death	eng
dc.type	Article	eng

Priority Updates to Research Literature (PURLs)
Priority Updates to Research Literature generate new evidence-based recommendations for practice for family physicians and other primary care clinicians.